Skip to main content
Premium Trial:

Request an Annual Quote

CMTP-Funded Effort to Develop Evidence Standards for NGS Cancer Testing

NEW YORK (GenomeWeb News) – The Center for Medical Technology Policy is funding a project that will develop guidance on evidence standards needed to evaluate next-generation sequencing-based tests for cancer diagnosis and treatment.

The CMTP-funded Green Park Collaborative is leading the effort via its Oncology Consortium.

The initiative aims to produce an Effectiveness Guidance Document that will inform decision making on coverage and reimbursement for NGS-based tests, CMTP said. Elisabeth Houtsmuller, senior program director for GPC, will direct the project, which will be led by a technical working group comprising representatives from health plans, the US Food and Drug Administration, the Centers for Medicare & Medicaid Services, NGS test developers, patient groups, oncology guideline organizations, clinical oncologists, drug/biologic companies, and other stakeholders.

CMTP said that the guidance document will focus on NGS-based tests used to manage patients with a known diagnosis of cancer, rather than risk prediction testing, and will be informed by its recent work on "evidentiary standards for studies of the clinical validity and clinical utility of molecular diagnostics in oncology."

CMTP said that the GPC's Oncology Consortium is also developing a guidance document on the best ways to use sequencing for research on cancer care treatments. This work is led by Donna Messner, research director at CMTP, and Anne Schott, a medical oncologist at the University of Michigan.

A CMTP official said the guidance documents should be available in the fourth quarter.

The Scan

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.